179 related articles for article (PubMed ID: 24785097)
1. RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).
Ezzeldin M; Borrego-Diaz E; Taha M; Esfandyari T; Wise AL; Peng W; Rouyanian A; Asvadi Kermani A; Soleimani M; Patrad E; Lialyte K; Wang K; Williamson S; Abdulkarim B; Olyaee M; Farassati F
Mol Oncol; 2014 Jul; 8(5):1043-53. PubMed ID: 24785097
[TBL] [Abstract][Full Text] [Related]
2. RalA is overactivated in medulloblastoma.
Ginn KF; Fangman B; Terai K; Wise A; Ziazadeh D; Shah K; Gartrell R; Ricke B; Kimura K; Mathur S; Borrego-Diaz E; Farassati F
J Neurooncol; 2016 Oct; 130(1):99-110. PubMed ID: 27566179
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
Tian L; Zhao L; Sze KM; Kam CS; Ming VS; Wang X; Zhang VX; Ho DW; Cheung TT; Chan LK; Ng IO
Hepatology; 2022 Jul; 76(1):48-65. PubMed ID: 34767674
[TBL] [Abstract][Full Text] [Related]
5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
6. Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma.
Kodama T; Bard-Chapeau EA; Newberg JY; Kodama M; Rangel R; Yoshihara K; Ward JM; Jenkins NA; Copeland NG
Gastroenterology; 2016 Aug; 151(2):324-337.e12. PubMed ID: 27178121
[TBL] [Abstract][Full Text] [Related]
7. Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.
Liu F; Wang G; Wang X; Che Z; Dong W; Guo X; Wang Z; Chen P; Hou D; Zhang Q; Zhang W; Pan Y; Yang D; Liu H
Oncotarget; 2017 Apr; 8(17):27953-27965. PubMed ID: 28427193
[TBL] [Abstract][Full Text] [Related]
8. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.
Lim KH; Brady DC; Kashatus DF; Ancrile BB; Der CJ; Cox AD; Counter CM
Mol Cell Biol; 2010 Jan; 30(2):508-23. PubMed ID: 19901077
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
[TBL] [Abstract][Full Text] [Related]
10. Ral overactivation in malignant peripheral nerve sheath tumors.
Bodempudi V; Yamoutpoor F; Pan W; Dudek AZ; Esfandyari T; Piedra M; Babovick-Vuksanovic D; Woo RA; Mautner VF; Kluwe L; Clapp DW; De Vries GH; Thomas SL; Kurtz A; Parada LF; Farassati F
Mol Cell Biol; 2009 Jul; 29(14):3964-74. PubMed ID: 19414599
[TBL] [Abstract][Full Text] [Related]
11. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
12. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
[TBL] [Abstract][Full Text] [Related]
13. Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Front Immunol; 2022; 13():1046044. PubMed ID: 36466919
[TBL] [Abstract][Full Text] [Related]
14. Ral signaling pathway in health and cancer.
Moghadam AR; Patrad E; Tafsiri E; Peng W; Fangman B; Pluard TJ; Accurso A; Salacz M; Shah K; Ricke B; Bi D; Kimura K; Graves L; Najad MK; Dolatkhah R; Sanaat Z; Yazdi M; Tavakolinia N; Mazani M; Amani M; Ghavami S; Gartell R; Reilly C; Naima Z; Esfandyari T; Farassati F
Cancer Med; 2017 Dec; 6(12):2998-3013. PubMed ID: 29047224
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
18. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
19. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
20. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
